Menu

Is Immunotherapy Living Up to Its Promise?

The Scientist is bringing together a panel of experts to weigh in on the progress that immunotherapy has made.

Jul 18, 2017
The Scientist Creative Services Team

Is Immunotherapy Living up to Its Promise? from thescientistllc on Vimeo

Immunotherapy has been hailed as a breakthrough for treating the untreatable, but it has not yet lived up to its promise to eradicate cancer and infectious disease. While there have been a number of exciting advances, there are still several real-world hurdles for immunotherapy to surmount before it becomes a standard option for most patients. The Scientist is bringing together a panel of experts to weigh in on the progress that immunotherapy has made, particularly in the search for effective anticancer treatments, and to discuss the steps still needed before immunotherapy becomes standard treatment in the clinic. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.

Topics to be covered:

  • Where immunotherapies have succeeded, and where they have failed
  • Current progress in immunotherapy research, development, and deployment

View the Video Now

Meet the Speakers:

Jill O’Donnell-Tormey, PhD
CEO and Director of Scientific Affairs
Cancer Research Institute

 

 

 

 

Alex Y. Huang, MD, PhD
Professor, Departments of Pediatrics,
Pathology, Biomedical Engineering,
and General Medical Sciences,
Case Western Reserve University School of Medicine,
UH Rainbow Babies & Children's Hospital

 

 


 

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.